Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioMark Diagnostics Inc C.BUX

Alternate Symbol(s):  BMKDF

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.


CSE:BUX - Post by User

BioMark Diagnostics Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by sailtakeron May 17, 2015 9:25am
136 Views
Post# 23737072

Interesting progress/ from website

Interesting progress/ from website

BioMark and Response to Treatment

By: superadmin | Tags: | Comments: 0 | May 16th, 2015

BioMark’s Principal Engineer attended the World Congress on Interventional Oncology (WCIO) May 6th – 9th in New York to discuss BioMark’s Response to Treatment program and how it would fit into the rapidly developing interventional oncology market place.

BioMark’s Principal Engineer spent the month of March in Japan, Taiwan and China to explore the opportunity to implement a Response to Treatment program in the region of the four Tigers (Japan, Korea, Taiwan and Hong Kong). Pioneers, key opinion and technical leaders in Asia have been introduced to BioMark’s technology and those leaders attending the WCIO will be meeting BioMark team again during the week of May 3rd to 9th. BioMark plans to discuss elements necessary to implement and manage its’ Asian Response to Treatment (ART) potential project in late 2015/2016 with luminary oncology centers in Tokyo, Osaka, Seoul, Taipei and Hong Kong.

BioMark’s CEO, Rashid Ahmed states, “We believe that the opportunities to introduce an ART program via the four Tigers represents a significant market opportunity, not to be ignored.” BioMark’s Response to Treatment program provides an excellent tool to provide interventional oncologists additional medical evidence to support efficacy of the procedures.

——–

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities